KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Esperion Therapeutics (ESPR) Notes Payables (2024 - 2025)

Esperion Therapeutics filings provide 2 years of Notes Payables readings, the most recent being $54.9 million for Q3 2025.

On a quarterly basis, Notes Payables changed N/A to $54.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $54.9 million, a N/A change, with the full-year FY2024 number at $54.6 million, changed N/A from a year prior.
Notes Payables hit $54.9 million in Q3 2025 for Esperion Therapeutics, roughly flat from $54.8 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $54.9 million in Q3 2025 to a low of $54.6 million in Q4 2024.